Bispecific Antibody-Based Immune-Cell Engagers and Their Emerging Therapeutic Targets in Cancer Immunotherapy

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2022 May 28

PMID 35628495

Authors

Ha Gyeong Shin

Ha Rim Yang

Aerin Yoon

Sukmook Lee

Affiliations

Soon will be listed here.

Abstract

Cancer is the second leading cause of death worldwide after cardiovascular diseases. Harnessing the power of immune cells is a promising strategy to improve the antitumor effect of cancer immunotherapy. Recent progress in recombinant DNA technology and antibody engineering has ushered in a new era of bispecific antibody (bsAb)-based immune-cell engagers (ICEs), including T- and natural-killer-cell engagers. Since the first approval of blinatumomab by the United States Food and Drug Administration (US FDA), various bsAb-based ICEs have been developed for the effective treatment of patients with cancer. Simultaneously, several potential therapeutic targets of bsAb-based ICEs have been identified in various cancers. Therefore, this review focused on not only highlighting the action mechanism, design and structure, and status of bsAb-based ICEs in clinical development and their approval by the US FDA for human malignancy treatment, but also on summarizing the currently known and emerging therapeutic targets in cancer. This review provides insights into practical considerations for developing next-generation ICEs.

Citing Articles

Harnessing the Power of NK Cell Receptor Engineering as a New Prospect in Cancer Immunotherapy.

Douka S, Papamoschou V, Raimo M, Mastrobattista E, Caiazzo M Pharmaceutics. 2024; 16(9).

PMID: 39339180 PMC: 11434712. DOI: 10.3390/pharmaceutics16091143.

Stepping forward: T-cell redirecting bispecific antibodies in cancer therapy.

Qin X, Ning W, Liu H, Liu X, Luo W, Xia N Acta Pharm Sin B. 2024; 14(6):2361-2377.

PMID: 38828136 PMC: 11143529. DOI: 10.1016/j.apsb.2024.03.027.

Rapid Access to Potent Bispecific T Cell Engagers Using Biogenic Tyrosine Click Chemistry.

Shajan I, Rochet L, Tracey S, Jackowska B, Benazza R, Hernandez-Alba O Bioconjug Chem. 2023; 34(12):2215-2220.

PMID: 37962868 PMC: 10739583. DOI: 10.1021/acs.bioconjchem.3c00357.

Targeting immune checkpoints: how to use natural killer cells for fighting against solid tumors.

Ghaedrahmati F, Esmaeil N, Abbaspour M Cancer Commun (Lond). 2022; 43(2):177-213.

PMID: 36585761 PMC: 9926962. DOI: 10.1002/cac2.12394.

Bispecific Antibodies: A Novel Approach for the Treatment of Solid Tumors.

Liguori L, Polcaro G, Nigro A, Conti V, Sellitto C, Perri F Pharmaceutics. 2022; 14(11).

PMID: 36432631 PMC: 9694302. DOI: 10.3390/pharmaceutics14112442.

References

Lehman J, Hoeksema M, Staub J, Qian J, Harris B, Callison J . Somatostatin receptor 2 signaling promotes growth and tumor survival in small-cell lung cancer. Int J Cancer. 2018; 144(5):1104-1114. PMC: 6448409. DOI: 10.1002/ijc.31771. View

Slade M, Uy G . CD123 bi-specific antibodies in development in AML: What do we know so far?. Best Pract Res Clin Haematol. 2020; 33(4):101219. DOI: 10.1016/j.beha.2020.101219. View

Daver N, Schlenk R, Russell N, Levis M . Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia. 2019; 33(2):299-312. PMC: 6365380. DOI: 10.1038/s41375-018-0357-9. View

van Loo P, Hangalapura B, Thordardottir S, Gibbins J, Veninga H, Hendriks L . MCLA-117, a CLEC12AxCD3 bispecific antibody targeting a leukaemic stem cell antigen, induces T cell-mediated AML blast lysis. Expert Opin Biol Ther. 2019; 19(7):721-733. DOI: 10.1080/14712598.2019.1623200. View

Tai Y, Mayes P, Acharya C, Zhong M, Cea M, Cagnetta A . Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood. 2014; 123(20):3128-38. PMC: 4023420. DOI: 10.1182/blood-2013-10-535088. View

Arruebo M, Vilaboa N, Saez-Gutierrez B, Lambea J, Tres A, Valladares M . Assessment of the evolution of cancer treatment therapies. Cancers (Basel). 2013; 3(3):3279-330. PMC: 3759197. DOI: 10.3390/cancers3033279. View

Liu J, Li L, Luo N, Liu Q, Liu L, Chen D . Inflammatory signals induce MUC16 expression in ovarian cancer cells via NF-κB activation. Exp Ther Med. 2021; 21(2):163. PMC: 7792485. DOI: 10.3892/etm.2020.9594. View

Zhang J, Yi J, Zhou P . Development of bispecific antibodies in China: overview and prospects. Antib Ther. 2021; 3(2):126-145. PMC: 7990247. DOI: 10.1093/abt/tbaa011. View

Gao Y, Mehta K . N-linked glycosylation of CD38 is required for its structure stabilization but not for membrane localization. Mol Cell Biochem. 2006; 295(1-2):1-7. DOI: 10.1007/s11010-006-9265-9. View

10.

Kloboves Prevodnik V, Lavrencak J, Horvat M, Novakovic B . The predictive significance of CD20 expression in B-cell lymphomas. Diagn Pathol. 2011; 6:33. PMC: 3083324. DOI: 10.1186/1746-1596-6-33. View

11.

Vitorino P, Chuang C, Iannello A, Zhao X, Anderson W, Ferrando R . Rova-T enhances the anti-tumor activity of anti-PD1 in a murine model of small cell lung cancer with endogenous Dll3 expression. Transl Oncol. 2020; 14(1):100883. PMC: 7569230. DOI: 10.1016/j.tranon.2020.100883. View

12.

Carter P . Bispecific human IgG by design. J Immunol Methods. 2001; 248(1-2):7-15. DOI: 10.1016/s0022-1759(00)00339-2. View

13.

Wang Q, Chen Y, Park J, Liu X, Hu Y, Wang T . Design and Production of Bispecific Antibodies. Antibodies (Basel). 2019; 8(3). PMC: 6783844. DOI: 10.3390/antib8030043. View

14.

Sanchez E, Li M, Kitto A, Li J, Wang C, Kirk D . Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival. Br J Haematol. 2012; 158(6):727-38. DOI: 10.1111/j.1365-2141.2012.09241.x. View

15.

Rader C . DARTs take aim at BiTEs. Blood. 2011; 117(17):4403-4. DOI: 10.1182/blood-2011-02-337691. View

16.

Elshiaty M, Schindler H, Christopoulos P . Principles and Current Clinical Landscape of Multispecific Antibodies against Cancer. Int J Mol Sci. 2021; 22(11). PMC: 8198225. DOI: 10.3390/ijms22115632. View

17.

Schlothauer T, Herter S, Koller C, Grau-Richards S, Steinhart V, Spick C . Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions. Protein Eng Des Sel. 2016; 29(10):457-466. DOI: 10.1093/protein/gzw040. View

18.

Ma J, Mo Y, Tang M, Shen J, Qi Y, Zhao W . Bispecific Antibodies: From Research to Clinical Application. Front Immunol. 2021; 12:626616. PMC: 8131538. DOI: 10.3389/fimmu.2021.626616. View

19.

Jasper G, Arun I, Venzon D, Kreitman R, Wayne A, Yuan C . Variables affecting the quantitation of CD22 in neoplastic B cells. Cytometry B Clin Cytom. 2010; 80(2):83-90. PMC: 7316386. DOI: 10.1002/cyto.b.20567. View

20.

Nair-Gupta P, Diem M, Reeves D, Wang W, Schulingkamp R, Sproesser K . A novel C2 domain binding CD33xCD3 bispecific antibody with potent T-cell redirection activity against acute myeloid leukemia. Blood Adv. 2020; 4(5):906-919. PMC: 7065489. DOI: 10.1182/bloodadvances.2019001188. View